BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Experts in dermatology, medical aesthetics, tissue engineering - ECPv6.18.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Experts in dermatology, medical aesthetics, tissue engineering
X-ORIGINAL-URL:https://www.rbcconsultants.com
X-WR-CALDESC:Events for Experts in dermatology, medical aesthetics, tissue engineering
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261029T190000
DTEND;TZID=America/New_York:20261029T200000
DTSTAMP:20261013T221228Z
CREATED:20261013T221228Z
LAST-MODIFIED:20261013T221228Z
UID:1752-1793300400-1793304000@www.rbcconsultants.com
SUMMARY:Pathways\, Patients\, and Practice Translating Psoriasis Pathophysiology
DESCRIPTION:Speaker: Bruce E. Strober\, MD\, PhD\, FAAD President\, International Psoriasis Council Clinical Professor of Dermatology\, Yale University School of Medicine Cromwell\, Connecticut \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Pathways\, Patients\, and Practice Translating Psoriasis Pathophysiology Into More Comprehensive Disease Management. A growing understanding of psoriasis biology is reshaping expectations for disease management. From inflammatory pathways and disease heterogeneity to systemic comorbidities and patient-reported burden\, this program examines the factors driving a more personalized and comprehensive approach to care\, including insights into key inflammatory signaling mediators within the complex network of pathways involved in psoriasis. \n  \nREGISTER
URL:https://www.rbcconsultants.com/event/pathways-patients-and-practice-translating-psoriasis-pathophysiology/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261028T190000
DTEND;TZID=America/New_York:20261028T200000
DTSTAMP:20261022T201231Z
CREATED:20261022T201231Z
LAST-MODIFIED:20261022T201231Z
UID:1755-1793214000-1793217600@www.rbcconsultants.com
SUMMARY:A Product Theater for Taltz® and Zepbound® Injection
DESCRIPTION:Speaker: Ganary Dabiri\, MD\, PhD Founder\, Inflammatory Skin & Obesity Medicine Clinic Dabiri Dermatology and Cosmetic Center Adjunct Assistant Professor\, Albany Medical College Diplomate\, American Board of Dermatology Diplomate\, American Board of Obesity Medicine Milford\, Massachusetts \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: A Product Theater for Taltz® and Zepbound® Injection Including an Affordability Solution for Eligible Taltz Patients Prescribed Zepbound. Beyond Skin and Joints: Concomitant Taltz (ixekizumab) and Zepbound (tirzepatide) for Adults with PsA/PsO and Obesity. \nREGISTER HERE
URL:https://www.rbcconsultants.com/event/a-product-theater-for-taltz-and-zepbound-injection-2/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261027T190000
DTEND;TZID=America/New_York:20261027T200000
DTSTAMP:20261013T221142Z
CREATED:20261013T221105Z
LAST-MODIFIED:20261013T221142Z
UID:1750-1793127600-1793131200@www.rbcconsultants.com
SUMMARY:The Evolving Landscape of Bullous Pemphigoid: Challenging Old Beliefs and Embracing New Insights
DESCRIPTION:Speakers: Daniel Butler\, MD Assistant Dean of Student Affairs Associate Professor University of Arizona College of Medicine Tucson\, AZ\, USA \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \n\nShow in my time zone\n\n\n\nPlease join us for our next IDF Educational Series Webinar: The Evolving Landscape of Bullous Pemphigoid: Challenging Old Beliefs and Embracing New Insights This ADVENT program will feature an expert-led presentation by Dr. DanielButler focused on addressing common misconceptions in bullous pemphigoid (BP). This session will review the clinical presentation and pathophysiology of BP\, including the heterogeneous nature of disease manifestations and the evolving understanding of type 2 inflammation. Dr. Butler will also examine the clinical implications of these concepts for recognizing and diagnosing BP in practice. Through expert insights and discussion\, this program aims to enhance clinical understanding of BP and support timely recognition of this complex disease.\n\n\n\nREGISTER
URL:https://www.rbcconsultants.com/event/the-evolving-landscape-of-bullous-pemphigoid-challenging-old-beliefs-and-embracing-new-insights/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261022T190000
DTEND;TZID=America/New_York:20261022T200000
DTSTAMP:20261013T221023Z
CREATED:20261013T221023Z
LAST-MODIFIED:20261013T221023Z
UID:1748-1792695600-1792699200@www.rbcconsultants.com
SUMMARY:Choose Fast Relief From Hives and Itch With RHAPSIDO®
DESCRIPTION:Speaker: April W. Armstrong\, MD\, FAAD University of California\, Los Angeles \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Choose Fast Relief From Hives and Itch With RHAPSIDO®: An Oral Targeted Treatment Approach for Uncontrolled Chronic Spontaneous Urticaria Despite Antihistamine Use. This presentation will explore a different approach in patient care with RHAPSIDO by explaining the role of Bruton’s tyrosine kinase (BTK) in CSU pathophysiology and MOA of RHAPSIDO as the first-of-its-kind oral BTK inhibitor (BTKi) therapy\, exploring clinical data on RHAPSIDO\, including efficacy\, safety\, and onset of action\, to support informed treatment decisions after antihistamines fall short\, and providing real-world perspectives from expert peers on how RHAPSIDO may help your appropriate patients. \n  \nREGISTER
URL:https://www.rbcconsultants.com/event/choose-fast-relief-from-hives-and-itch-with-rhapsido-5/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261020T190000
DTEND;TZID=America/New_York:20261020T200000
DTSTAMP:20261007T161142Z
CREATED:20261007T161142Z
LAST-MODIFIED:20261007T161142Z
UID:1746-1792522800-1792526400@www.rbcconsultants.com
SUMMARY:Working Against Moderate-to-Severe Atopic Dermatitis
DESCRIPTION:Speakers: Angela J. Lamb\, MD Board-Certified Dermatologist Associate Professor of Dermatology\, Icahn School of Medicine at Mount Sinai System Vice Chair of Clinical Operations and Strategy\, Mount Sinai Health System New York\, New York \n  \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Day In Day Out. Adbry®: Working Against Moderate-to-Severe Atopic Dermatitis \nRegistration
URL:https://www.rbcconsultants.com/event/working-against-moderate-to-severe-atopic-dermatitis/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261015T190000
DTEND;TZID=America/New_York:20261015T200000
DTSTAMP:20261007T160829Z
CREATED:20261007T160734Z
LAST-MODIFIED:20261007T160829Z
UID:1743-1792090800-1792094400@www.rbcconsultants.com
SUMMARY:Derm Portfolio: Expanding Treatment Possibilities in Moderate to Severe Plaque Psoriasis
DESCRIPTION:Speaker: Brad Glick\, DO\, MPH\, FAAD Director of Dermatology Residency Training\, Larkin Health Systems – Palm Springs Clinical Assistant Professor of Dermatology FIU Herbert Wertheim College of Medicine – Miami Founder\, Glick Skin Institute Member of the Board of Directors\, American Academy of Dermatology \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Derm Portfolio: Expanding Treatment Possibilities in Moderate to Severe Plaque Psoriasis \n  \nRegistration
URL:https://www.rbcconsultants.com/event/derm-portfolio-expanding-treatment-possibilities-in-moderate-to-severe-plaque-psoriasis/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261013T190000
DTEND;TZID=America/New_York:20261013T200000
DTSTAMP:20260928T113133Z
CREATED:20260928T113132Z
LAST-MODIFIED:20260928T113133Z
UID:1740-1791918000-1791921600@www.rbcconsultants.com
SUMMARY:Advancing Care in Moderate-to-Severe Atopic Dermatitis: Disease Insights and Emerging Targeted Therapies
DESCRIPTION:Speakers: Shawn G. Kwatra\, MD\, FAAD and Walter J. Liszewski\, MD\, FAAD \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Advancing Care in Moderate-to-Severe Atopic Dermatitis: Disease Insights and Emerging Targeted Therapies. Deeper Understanding of Atopic Dermatitis This educational webinar will provide an overview of moderate-to-severe atopic dermatitis as a chronic\, relapsing inflammatory disease driven by underlying type 2 immune dysregulation and skin barrier dysfunction. Shawn G. Kwatra\, MD\, FAAD will review the clinical presentation\, disease burden\, and impact on patients’ quality of life\, including pruritus\, sleep disturbance\, and psychosocial effects. The session will also highlight current challenges in disease management and ongoing unmet needs\, offering insights to support a deeper understanding of atopic dermatitis and inform clinical decision-making. EBGLYSS®(lebrikizumab-lbkz): What could less mean for your patients? Join your colleagues for a peer discussion exploring the latest EBGLYSS data. This program is sponsored by\, and the speaker is presenting on behalf of\, Lilly USA\, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit. Please see Prescribing Information and Patient Information at the product theater or on https://ebglyss.lilly.com. Please see Instructions for use included with the device. EBGLYSS® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company\, its subsidiaries\, or affiliates. \n  \nREGISTER HERE
URL:https://www.rbcconsultants.com/event/advancing-care-in-moderate-to-severe-atopic-dermatitis-disease-insights-and-emerging-targeted-therapies-4/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260924T190000
DTEND;TZID=America/New_York:20260924T200000
DTSTAMP:20260917T204648Z
CREATED:20260917T204648Z
LAST-MODIFIED:20260917T204648Z
UID:1737-1790276400-1790280000@www.rbcconsultants.com
SUMMARY:Demand More With BIMZELX: Transformative Results for Managing Hidradenitis Suppurative
DESCRIPTION:Speaker: Adam Friedman\, MD\, FAAD Professor & Chair of Dermatology\, George Washington University School of Medicine & Health Sciences Washington\, DC \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Demand More With BIMZELX: Transformative Results for Managing Hidradenitis Suppurative \n  \nCLICK HERE TO REGISTER
URL:https://www.rbcconsultants.com/event/demand-more-with-bimzelx-transformative-results-for-managing-hidradenitis-suppurative/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260923T190000
DTEND;TZID=America/New_York:20260923T200000
DTSTAMP:20260831T115726Z
CREATED:20260831T115726Z
LAST-MODIFIED:20260831T115726Z
UID:1729-1790190000-1790193600@www.rbcconsultants.com
SUMMARY:Shaping the Future of MIBC and Locally Advanced or mUC Management With PADCEV® + Pembrolizumab
DESCRIPTION:Speaker: Devesh Pandya\, MD Oncology Consultants\, PA \nModerator: Mario E. Lacouture\, MD\, FAAD Founding President\, Oncodermatology Society Chief\, Dermatology Division\, Department of Medicine NYU Grossman Long Island School of Medicine Medical Director\, Symptom Management Program Perlmutter Cancer Center NYU Langone Hospital – Long Island \nPlease join us for our next ODS Educational Series Webinar: Shaping the Future of MIBC and Locally Advanced or mUC Management With PADCEV® + Pembrolizumab. This presentation explores the evolving treatment landscape for muscle-invasive bladder cancer (MIBC) and locally advanced/metastatic urothelial cancer (la/mUC)\, highlighting historical unmet needs\, key efficacy and safety data for perioperative and systemic treatment approaches\, and the importance of multidisciplinary collaboration to optimize patient outcomes. The program aims to provide attendees with practical insights that can support informed treatment decision-making and enhance collaborative patient care. \n  \nREGISTER HERE
URL:https://www.rbcconsultants.com/event/shaping-the-future-of-mibc-and-locally-advanced-or-muc-management-with-padcev-pembrolizumab/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260922T190000
DTEND;TZID=America/New_York:20260922T200000
DTSTAMP:20260814T194808Z
CREATED:20260814T194808Z
LAST-MODIFIED:20260814T194808Z
UID:1723-1790103600-1790107200@www.rbcconsultants.com
SUMMARY:Discover the Science of VTAMA
DESCRIPTION:Speaker: Mona Shahriari\, MD\, FAAD Assistant Clinical Professor\, Department of Dermatology\, Yale University School of Medicine New Haven\, Connecticut \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Discover the Science of VTAMA \nREGISTER HERE
URL:https://www.rbcconsultants.com/event/discover-the-science-of-vtama-3/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260917T190000
DTEND;TZID=America/New_York:20260917T200000
DTSTAMP:20260831T121117Z
CREATED:20260831T121117Z
LAST-MODIFIED:20260831T121117Z
UID:1731-1789671600-1789675200@www.rbcconsultants.com
SUMMARY:Choose Fast Relief From Hives and Itch With RHAPSIDO®
DESCRIPTION:Speaker: Michelle Tarbox\, MD Associate Professor of Dermatology and Dermatopathology Chair and Program Director Texas Tech University Health Sciences Center Lubbock\, Texas \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Choose Fast Relief From Hives and Itch With RHAPSIDO®: An Oral Targeted Treatment Approach for Uncontrolled Chronic Spontaneous Urticaria Despite Antihistamine Use. This presentation will explore a different approach in patient care with RHAPSIDO by explaining the role of Bruton’s tyrosine kinase (BTK) in CSU pathophysiology and MOA of RHAPSIDO as the first-of-its-kind oral BTK inhibitor (BTKi) therapy\, exploring clinical data on RHAPSIDO\, including efficacy\, safety\, and onset of action\, to support informed treatment decisions after antihistamines fall short\, and providing real-world perspectives from expert peers on how RHAPSIDO may help your appropriate patients. \n  \nREGISTER HERE
URL:https://www.rbcconsultants.com/event/choose-fast-relief-from-hives-and-itch-with-rhapsido-4/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260916T190000
DTEND;TZID=America/New_York:20260916T200000
DTSTAMP:20260908T114538Z
CREATED:20260908T114538Z
LAST-MODIFIED:20260908T114538Z
UID:1734-1789585200-1789588800@www.rbcconsultants.com
SUMMARY:Discover ZORYVE® (roflumilast): A Case-based Perspective
DESCRIPTION:Speakers: Neal Bhatia\, MD Director of Clinical Dermatology Therapeutics Clinical Research San Diego\, California and Ted Lain\, MD\, MBA Chief Medical Officer Sanova Dermatology Austin\, Texas \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Discover ZORYVE® (roflumilast): A Case-based Perspective. Neal Bhatia\, MD and Ted Lain\, MD\, MBA will discuss latest innovation in topical therapies. \n  \nREGISTER HERE
URL:https://www.rbcconsultants.com/event/discover-zoryve-roflumilast-a-case-based-perspective/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260910T190000
DTEND;TZID=America/New_York:20260910T200000
DTSTAMP:20260805T204731Z
CREATED:20260805T204731Z
LAST-MODIFIED:20260805T204731Z
UID:1713-1789066800-1789070400@www.rbcconsultants.com
SUMMARY:Earlier Intervention with COSENTYX® (secukinumab) and Long-Term Impact
DESCRIPTION:Speaker: William D. Shipman III\, MD\, PhD\, FAAD Board-Certified Dermatologist\, Skin & Beauty Center Adjunct Clinical Assistant Professor of Dermatology University of Southern California \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Earlier Intervention with COSENTYX® (secukinumab) and Long-Term Impact \nREGISTER HERE
URL:https://www.rbcconsultants.com/event/earlier-intervention-with-cosentyx-secukinumab-and-long-term-impact/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260827T190000
DTEND;TZID=America/New_York:20260827T200000
DTSTAMP:20260825T003439Z
CREATED:20260814T195018Z
LAST-MODIFIED:20260825T003439Z
UID:1725-1787857200-1787860800@www.rbcconsultants.com
SUMMARY:Choose Fast Relief From Hives and Itch With RHAPSIDO®
DESCRIPTION:Speaker: Aaron Farberg\, MD\, FAAD Chief Medical Officer & Founding Partner\, Bare Dermatology Assistant Professor\, Baylor Scott & White Health System University of North Texas Health Science Center Dallas\, Texas \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Choose Fast Relief From Hives and Itch With RHAPSIDO®: An Oral Targeted Treatment Approach for Uncontrolled Chronic Spontaneous Urticaria Despite Antihistamine Use. This presentation will explore a different approach in patient care with RHAPSIDO by explaining the role of Bruton’s tyrosine kinase (BTK) in CSU pathophysiology and MOA of RHAPSIDO as the first-of-its-kind oral BTK inhibitor (BTKi) therapy\, exploring clinical data on RHAPSIDO\, including efficacy\, safety\, and onset of action\, to support informed treatment decisions after antihistamines fall short\, and providing real-world perspectives from expert peers on how RHAPSIDO may help your appropriate patients. \n  \nREGISTER HERE \n 
URL:https://www.rbcconsultants.com/event/choose-fast-relief-from-hives-and-itch-with-rhapsido-3/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260825T190000
DTEND;TZID=America/New_York:20260825T200000
DTSTAMP:20260814T194605Z
CREATED:20260814T194605Z
LAST-MODIFIED:20260814T194605Z
UID:1721-1787684400-1787688000@www.rbcconsultants.com
SUMMARY:From Clinical Trials to Clinical Practice; A closer look at Bimzelx MOA\, Efficacy\, and Safety
DESCRIPTION:Speakers: G. Michael Lewitt\, MD Partner\, Illinois Dermatology Institute Director of Medical Dermatology Research\, DeNova Research Associate Professor of Dermatology\, Rosalind Franklin University Chicago Medical School and Andrew Mastro\, MS\, PA-C Board-Certified Physician Assistant\, Illinois Dermatology Institute Sub-Investigator\, DeNova Research Lecturer/Preceptor\, Rush University College of Health Sciences\n\n\n\n\n\n\n\n\n\nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY\nPlease join us for our next IDF Educational Series Webinar: From Clinical Trials to Clinical Practice; A closer look at Bimzelx MOA\, Efficacy\, and Safety.\n\nREGISTER HERE
URL:https://www.rbcconsultants.com/event/from-clinical-trials-to-clinical-practice-a-closer-look-at-bimzelx-moa-efficacy-and-safety/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260824T190000
DTEND;TZID=America/New_York:20260824T200000
DTSTAMP:20260805T203739Z
CREATED:20260805T203619Z
LAST-MODIFIED:20260805T203739Z
UID:1709-1787598000-1787601600@www.rbcconsultants.com
SUMMARY:Day In & Day Out. Adbry®: Working Against Moderate-to-Severe Atopic Dermatitis
DESCRIPTION:Speakers: David Cotter\, MD\, PhD Partner and Director of Clinical Research Las Vegas Dermatology Clinical Assistant Professor of Internal Medicine and Dermatology\, University of Nevada\, Las Vegas School of Medicine Las Vegas\, Nevada \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Day In & Day Out. Adbry®: Working Against Moderate-to-Severe Atopic Dermatitis \n  \nREGISTER HERE
URL:https://www.rbcconsultants.com/event/day-in-day-out-adbry-working-against-moderate-to-severe-atopic-dermatitis/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260820T190000
DTEND;TZID=America/New_York:20260820T200000
DTSTAMP:20260813T135334Z
CREATED:20260813T135324Z
LAST-MODIFIED:20260813T135334Z
UID:1719-1787252400-1787256000@www.rbcconsultants.com
SUMMARY:A Product Theater for Taltz® and Zepbound® Injection
DESCRIPTION:Speaker: Ganary Dabiri\, MD\, PhD Founder\, Inflammatory Skin & Obesity Medicine Clinic Dabiri Dermatology and Cosmetic Center Adjunct Assistant Professor\, Albany Medical College Diplomate\, American Board of Dermatology Diplomate\, American Board of Obesity Medicine Milford\, Massachusetts \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: A Product Theater for Taltz® and Zepbound® Injection Including an Affordability Solution for Eligible Taltz Patients Prescribed Zepbound. Beyond Skin and Joints: Concomitant Taltz (ixekizumab) and Zepbound (tirzepatide) for Adults with PsA/PsO and Obesity. \nREGISTER HERE
URL:https://www.rbcconsultants.com/event/a-product-theater-for-taltz-and-zepbound-injection/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260818T190000
DTEND;TZID=America/New_York:20260818T200000
DTSTAMP:20260805T204910Z
CREATED:20260805T204910Z
LAST-MODIFIED:20260805T204910Z
UID:1715-1787079600-1787083200@www.rbcconsultants.com
SUMMARY:Earlier Intervention with COSENTYX® (secukinumab) and Long-Term Impact
DESCRIPTION:Speaker: Collin Blattner\, DO\, FAAD Double Board-Certified Dermatologist Fellowship-Trained Mohs Micrographic Skin Cancer Surgeon \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Earlier Intervention with COSENTYX® (secukinumab) and Long-Term Impact \nREGISTER HERE
URL:https://www.rbcconsultants.com/event/earlier-intervention-with-cosentyx-secukinumab-and-long-term-impact-2/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260813T190000
DTEND;TZID=America/New_York:20260813T200000
DTSTAMP:20260804T175208Z
CREATED:20260804T175208Z
LAST-MODIFIED:20260804T175208Z
UID:1707-1786647600-1786651200@www.rbcconsultants.com
SUMMARY:Beyond the Assumptions: Dispelling Misconceptions About Pediatric AD
DESCRIPTION:Speakers: Lawrence Eichenfield\, MD\, FAAD University of California San Diego Rady Children’s Hospital San Diego\, California and John Browning\, MD\, FAAD\, FAAP\, MBA​ Texas Dermatology and Laser Specialists San Antonio\, TX \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Beyond the Assumptions: Dispelling Misconceptions About Pediatric AD. This ADVENT program will feature a comprehensive presentation led by Dr. Larry Eichenfield and Dr. John Browning\, focusing on common misconceptions around pediatric atopic dermatitis (AD). The session will explore the connection between pediatric AD and the development of food allergy\, the unique roles of type 2 inflammatory cytokines in AD pathogenesis\, and how the burden of pediatric AD can extend beyond the skin. Through expert insights and evidence-based discussion\, the program aims to clarify key concepts in AD pathophysiology and to discuss lasting disease burden\, ultimately enhancing clinical understanding and improving prompt care for pediatric patients with AD. \n  \nREGISTER HERE
URL:https://www.rbcconsultants.com/event/beyond-the-assumptions-dispelling-misconceptions-about-pediatric-ad/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260811T190000
DTEND;TZID=America/New_York:20260811T200000
DTSTAMP:20260730T024504Z
CREATED:20260730T024504Z
LAST-MODIFIED:20260730T024504Z
UID:1705-1786474800-1786478400@www.rbcconsultants.com
SUMMARY:Advancing Care in Moderate-to-Severe Atopic Dermatitis: Disease Insights and Emerging Targeted Therapies
DESCRIPTION:Speakers: Angela Lamb\, MD\, FAAD and Naiem T. Issa\, MD\, PhD\, FAAD \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Advancing Care in Moderate-to-Severe Atopic Dermatitis: Disease Insights and Emerging Targeted Therapies. Skin Deep: Atopic Dermatitis in Women. Sex-Specific Considerations in Diagnosis\, Triggers & Management Dr. Angela Lamb will review the epidemiology and pathophysiology of atopic dermatitis in women\, highlighting the influence of hormonal changes\, psychosocial stressors\, cosmetics\, occupational exposures\, and reproductive milestones on disease activity. The session will provide practical\, evidence-based guidance for managing atopic dermatitis in sensitive areas\, including the face\, eyelids\, nipple/areola\, and vulvar region\, while discussing treatment considerations for pregnancy\, lactation\, menopause\, and women of reproductive age. EBGLYSS®(lebrikizumab-lbkz): What could less mean for your patients? Join your colleagues for a peer discussion exploring the latest EBGLYSS data. This program is sponsored by\, and the speaker is presenting on behalf of\, Lilly USA\, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit. Please see Prescribing Information and Patient Information at the product theater or on https://ebglyss.lilly.com. Please see Instructions for use included with the device. EBGLYSS® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company\, its subsidiaries\, or affiliates. \nREGISTER HERE
URL:https://www.rbcconsultants.com/event/advancing-care-in-moderate-to-severe-atopic-dermatitis-disease-insights-and-emerging-targeted-therapies-3/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260728T190000
DTEND;TZID=America/New_York:20260728T200000
DTSTAMP:20260721T171935Z
CREATED:20260721T171935Z
LAST-MODIFIED:20260721T171935Z
UID:1702-1785265200-1785268800@www.rbcconsultants.com
SUMMARY:Advancing Care in Moderate-to-Severe Atopic Dermatitis: Disease Insights and Emerging Targeted Therapies
DESCRIPTION:Speakers: Ali Shahbaz\, MD\, FAAD\, FRCPC and Tina Bhutani\, MD\, MAS \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Advancing Care in Moderate-to-Severe Atopic Dermatitis: Disease Insights and Emerging Targeted Therapies. Deeper Understanding of Atopic Dermatitis This educational webinar will provide an overview of moderate-to-severe atopic dermatitis as a chronic\, relapsing inflammatory disease driven by underlying type 2 immune dysregulation and skin barrier dysfunction. Ali Shahbaz\, MD\, FAAD\, FRCPC will review the clinical presentation\, disease burden\, and impact on patients’ quality of life\, including pruritus\, sleep disturbance\, and psychosocial effects. The session will also highlight current challenges in disease management and ongoing unmet needs\, offering insights to support a deeper understanding of atopic dermatitis and inform clinical decision-making. EBGLYSS®(lebrikizumab-lbkz): What could less mean for your patients? Join your colleagues for a peer discussion exploring the latest EBGLYSS data. This program is sponsored by\, and the speaker is presenting on behalf of\, Lilly USA\, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit. Please see Prescribing Information and Patient Information at the product theater or on https://ebglyss.lilly.com. Please see Instructions for use included with the device. EBGLYSS® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company\, its subsidiaries\, or affiliates. \n  \nREGISTER
URL:https://www.rbcconsultants.com/event/advancing-care-in-moderate-to-severe-atopic-dermatitis-disease-insights-and-emerging-targeted-therapies-2/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260723T190000
DTEND;TZID=America/New_York:20260723T200000
DTSTAMP:20260708T111130Z
CREATED:20260708T111130Z
LAST-MODIFIED:20260708T111130Z
UID:1697-1784833200-1784836800@www.rbcconsultants.com
SUMMARY:Bridging Care Across Skin & Joints: An Option to Choose TREMFYA First
DESCRIPTION:Speaker: Adrian Rodriguez\, MD Board Certified Dermatologist Nashville Skin: Comprehensive Dermatology Center Advanced Research Experts\, PLC Adjunct Clinical Faculty\, University of Tennessee Health Science Center Nashville\, Tennessee \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Bridging Care Across Skin & Joints: An Option to Choose TREMFYA First \n  \nREGISTER
URL:https://www.rbcconsultants.com/event/bridging-care-across-skin-joints-an-option-to-choose-tremfya-first/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260720T190000
DTEND;TZID=America/New_York:20260720T200000
DTSTAMP:20260708T112151Z
CREATED:20260708T112014Z
LAST-MODIFIED:20260708T112151Z
UID:1699-1784574000-1784577600@www.rbcconsultants.com
SUMMARY:A Joint Approach to Psoriatic Disease Management: Bimzlex for your Patients with PsO and PsA
DESCRIPTION:Speakers: Saakshi Khattri\, MD\, MBBS\, FAAD\, FACR Director\, Dermatology/Rheumatology Service Icahn School of Medicine\, Mount Sinai  New York\, New York and Gordan K. Lam MD Board-Certified Rheumatologist Atrium Health Carolinas Medical Center \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: A Joint Approach to Psoriatic Disease Management: Bimzlex for your Patients with PsO and PsA. Bimzelx is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy\, active psoriatic arthritis\, active non radiographic axial spondyloarthritis with objective signs of inflammation\, active ankylosing spondylitis\, and moderate to severe hidradenitis suppurativa. \n  \nREGISTER
URL:https://www.rbcconsultants.com/event/a-joint-approach-to-psoriatic-disease-management-bimzlex-for-your-patients-with-pso-and-psa/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260714T190000
DTEND;TZID=America/New_York:20260714T200000
DTSTAMP:20260623T120504Z
CREATED:20260623T120504Z
LAST-MODIFIED:20260623T120504Z
UID:1693-1784055600-1784059200@www.rbcconsultants.com
SUMMARY:Choose Fast Relief From Hives and Itch With RHAPSIDO®
DESCRIPTION:Speaker: Michael J. Payette\, MD\, MBA\, FAAD Co-Founder and Dermatologist\, Central Connecticut Dermatology Dermatologist\, Middlesex Health Associate Editor\, Dermatology In-Review Cromwell\, Connecticut \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Choose Fast Relief From Hives and Itch With RHAPSIDO®: An Oral Targeted Treatment Approach for Uncontrolled Chronic Spontaneous Urticaria Despite Antihistamine Use. This presentation will explore a different approach in patient care with RHAPSIDO by explaining the role of Bruton’s tyrosine kinase (BTK) in CSU pathophysiology and MOA of RHAPSIDO as the first-of-its-kind oral BTK inhibitor (BTKi) therapy\, exploring clinical data on RHAPSIDO\, including efficacy\, safety\, and onset of action\, to support informed treatment decisions after antihistamines fall short\, and providing real-world perspectives from expert peers on how RHAPSIDO may help your appropriate patients. \n  \nREGISTER
URL:https://www.rbcconsultants.com/event/choose-fast-relief-from-hives-and-itch-with-rhapsido-2/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260709T190000
DTEND;TZID=America/New_York:20260709T200000
DTSTAMP:20260625T124943Z
CREATED:20260625T124943Z
LAST-MODIFIED:20260625T124943Z
UID:1695-1783623600-1783627200@www.rbcconsultants.com
SUMMARY:Earlier Intervention in HS With COSENTYX® (secukinumab) and Long-Term Impact
DESCRIPTION:Speaker: Leonardo Tjahjono\, MD\, FAAD Board-Certified Dermatologist Assistant Professor of Dermatology Co-Director of Hidradenitis Suppurativa Clinic Director of Inpatient Dermatology George Washington University School of Medicine Washington\, DC \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Earlier Intervention in HS With COSENTYX® (secukinumab) and Long-Term Impact This presentation will review the following key considerations in HS management: – When a patient with HS is ready for biologic therapy – What constitutes “moderate” HS – How patient-reported outcomes aid in HS severity assessment – What earlier intervention with biologic therapy can mean for patients \n  \nREGISTER
URL:https://www.rbcconsultants.com/event/earlier-intervention-in-hs-with-cosentyx-secukinumab-and-long-term-impact/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260625T200000
DTEND;TZID=America/New_York:20260625T210000
DTSTAMP:20260603T120406Z
CREATED:20260603T120406Z
LAST-MODIFIED:20260603T120406Z
UID:1672-1782417600-1782421200@www.rbcconsultants.com
SUMMARY:The Science of Hyaluronic Acid\, Skin Volumization\, and Regenerative Topical Innovation
DESCRIPTION:Speaker: Shino Bay\, DO Board-Certified Dermatologist Founder\, Owner\, and Medical Director Shino Bay Cosmetic Dermatology & Laser Institute Fort Lauderdale\, Florida \nModerator: Roxane Chabot President RBC Consultants \nPlease join us for our next RBC Consultants Educational Series Webinar: Beyond Hydration: The Science of Hyaluronic Acid\, Skin Volumization\, and Regenerative Topical Innovation Join Shino Bay\, DO\, internationally recognized dermatologist\, cosmetic dermatologic surgeon\, and educator\, for an in-depth exploration of the evolving science of hyaluronic acid in skin aging\, structural integrity\, and facial rejuvenation. This presentation will examine the biological role of hyaluronic acid beyond hydration\, including its influence on dermal architecture\, extracellular matrix signaling\, and age-related volume loss. Dr. Bay will review emerging advances in topical HA technology\, including novel conjugated hyaluronic acid platforms designed to enhance stability\, penetration\, biomarker activation\, and visible skin volumization. Clinical\, histologic\, and instrumental study findings will be discussed\, highlighting outcomes in plumpness\, contour\, skin quality\, hydration\, and barrier function. Attendees will gain practical insight into the future of regenerative topical skincare and evidence-based approaches for addressing visible signs of skin aging and structural volume loss. \nREGISTER
URL:https://www.rbcconsultants.com/event/the-science-of-hyaluronic-acid-skin-volumization-and-regenerative-topical-innovation/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260624T190000
DTEND;TZID=America/New_York:20260624T200000
DTSTAMP:20260611T193049Z
CREATED:20260611T192916Z
LAST-MODIFIED:20260611T193049Z
UID:1677-1782327600-1782331200@www.rbcconsultants.com
SUMMARY:EBGLYSS®(lebrikizumab-lbkz): What could less mean for your patients?
DESCRIPTION:Speaker: Sam Awan\, MD\, FAAD Board-certified Dermatologist U.S. Dermatology Partners McKinney\, Texas Baylor Scott & White Health Southwestern Health Resources \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: EBGLYSS®(lebrikizumab-lbkz): What could less mean for your patients? Join your colleagues for a peer discussion exploring the latest EBGLYSS data. This program is sponsored by\, and the speaker is presenting on behalf of\, Lilly USA\, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit. Please see Prescribing Information and Patient Information at the product theater or on https://ebglyss.lilly.com. Please see Instructions for Use included with the device. EBGLYSS® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company\, its subsidiaries\, or affiliates. \n  \nREGISTER
URL:https://www.rbcconsultants.com/event/ebglysslebrikizumab-lbkz-what-could-less-mean-for-your-patients/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260618T190000
DTEND;TZID=America/New_York:20260618T200000
DTSTAMP:20260604T195842Z
CREATED:20260604T195842Z
LAST-MODIFIED:20260604T195842Z
UID:1675-1781809200-1781812800@www.rbcconsultants.com
SUMMARY:Choose Fast Relief From Hives and Itch With RHAPSIDO®
DESCRIPTION:Speakers: Brad Peter Glick\, DO\, MPH\, FAAD\, FAOCD\, FACOFP Dermatologist\, Dermatologic Surgeon and Principal Investigator Larkin Health System – GSI Clinical Research Miami\, Florida \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Choose Fast Relief From Hives and Itch With RHAPSIDO®: An Oral Targeted Treatment Approach for Uncontrolled Chronic Spontaneous Urticaria Despite Antihistamine Use This presentation will explore a different approach in patient care with RHAPSIDO by explaining the role of Bruton’s tyrosine kinase (BTK) in CSU pathophysiology and MOA of RHAPSIDO as the first-of-its-kind oral BTK inhibitor (BTKi) therapy\, exploring clinical data on RHAPSIDO\, including efficacy\, safety\, and onset of action\, to support informed treatment decisions after antihistamines fall short\, and providing real-world perspectives from expert peers on how RHAPSIDO may help your appropriate patients. \nREGISTER
URL:https://www.rbcconsultants.com/event/choose-fast-relief-from-hives-and-itch-with-rhapsido/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260609T190000
DTEND;TZID=America/New_York:20260609T200000
DTSTAMP:20260519T133211Z
CREATED:20260519T133211Z
LAST-MODIFIED:20260519T133211Z
UID:1667-1781031600-1781035200@www.rbcconsultants.com
SUMMARY:Discover the Science of VTAMA
DESCRIPTION:Speaker: Ben Ehst\, MD\, PhD Co-owner\, Chief Medical Officer (CMO) and Principal Investigator\, Oregon Medical Research Center Clinical Associate Professor\, Department of Dermatology\, Oregon Health & Science University Portland\, Oregon \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Discover the Science of VTAMA \nREGISTER HERE
URL:https://www.rbcconsultants.com/event/discover-the-science-of-vtama-2/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260521T190000
DTEND;TZID=America/New_York:20260521T200000
DTSTAMP:20260410T173029Z
CREATED:20260410T173029Z
LAST-MODIFIED:20260410T173029Z
UID:1647-1779390000-1779393600@www.rbcconsultants.com
SUMMARY:Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema
DESCRIPTION:Speaker: April W. Armstrong MD\, FAAD Professor and Chief of Dermatology UCLA Health Professor of Dermatology Associate Dean for Clinical Research Director of Clinical Research Support\, Southern California Clinical and Translational Science Institute \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema. Join April W. Armstrong\, MD\, MPH\, for a review of expert consensus on advanced topical nonsteroidal therapies for chronic hand eczema. This session highlights their role as effective\, steroid-sparing options\, particularly delgocitinib\, focusing on efficacy\, safety\, and quality-of-life improvements to support clinical decision-making. \nRegister
URL:https://www.rbcconsultants.com/event/expert-consensus-on-advanced-topical-nonsteroidal-therapies-for-chronic-hand-eczema/
END:VEVENT
END:VCALENDAR